SLAS亚洲AntibodyDiscovering研讨会10月专场诚邀加入

　　会议主题：Antibody Discovering

　　主办单位：SLAS, SIAIS(上海科技大学免疫化学研究所)

　　会议时间时间：2014年10月23日12:15-16:00

　　会议地点：上海张江海科路100号行政楼一楼礼堂

　　注册费用：免费 (Shuttle Bus and Lunch Provided** please see the bottom of the page)

　　报名链接：http://asia-slas.org/registration.aspx?info_lb=25&flag=4&id=129

　　报名邮箱： asia@slas.org 注明报名参加六月上海研讨会，姓名、电话、手机、公司、职位等联系方式。

       电话报名：021-2312 3644

　　赞助联系： kyang@slas.org   021-2312 3644

　　日程安排：

　　12:15-13:15 Lunch Session

　　13:30-13:40 Main Session Introduction

　　13:40-14:20 Cell Based Hybridoma Screening for Therapeutic Antibody Discovery

　　This talk will be based on an internal case study project in his company and share with colleagues in academia or industry our experiences with cell based hybridoma screening.

　　Duan Qing, Principal Scientist, Biologics, Shanghai Chempartner

　　Dr. Duan has the extensive experience in drug discovery for both small molecular cmpds and therapeutic antibodies. Strong record of productivity in deleverying multiple drug candidates for downstream development. He got the Ph.D. from Institute of Health Science, Shanghai Institutes for Biological Science, Chinese Academy of Sciences.

　　14:20-15:00 Innovation and Modern Medicine: Discovering Novel Biotherapeutics

　　Since its birth 40 years ago, biotherapeutics have changed from simple recombinant proteins to engineered therapeutic proteins and antibodies, and to cell therapy and gene therapy. In fact, biotherapeutics have become an important component of modern medicine. The technology advancement for genetic engineering made it possible to create safe and efficacious biological drugs used to treat disease such as rheumatoid arthritis, multiple sclerosis, bone degeneration and cancer. This presentation will review the evolving biotherapeutic modalities and the technologies used for their generation.

　　Zhijian Lu, Head of Biologics Discovery Unit, Novartis Shanghai

　　Dr. Zhijian Lu has a Bachelor’s degree in chemistry from Jilin University, China, and a PhD degree from Boston University. He did his post-doctoral studies in Dr. Gobind Khorana’s lab in MIT on structure-function relationship of rhodopsin. Dr. Lu started working in Genetics Institute/Wyeth/Pfizer 20 years ago, where his researches were in the areas of cytokine structure/function studies, signal transduction/functional proteomics, and the discovery of biotherapeutics including recombinant proteins and monoclonal antibodies. He joint Novartis in 2011 as the head of Novartis biologics discovery unit in Shanghai.

　　15:00-15:20 Coffee Break

　　15:20-16:00 Combinatorial Antibody Library, Theory & Applications

　　Combinatorial antibody libraries have changed the face of immunochemistry because they allow construction of an immune system in a test tube. The diversity of such systems it a least three In orders of magnitude larger than the natural repertoire. The key to the selection process has been the linkage between recognition and replication in phage, yeast, or bacterial systems. Recently, such libraries have been incorporated into lentiviruses for phenotypic selections. Such selections are most powerful when they are autocrine based. In this talk, Dr. Yang will present results that demonstrate the power of this approach.

　　Guang Yang, Deputy Director, Shanghai Institute for Advanced Immunochemical Studies, Shanghai Tech University

　　Dr. Guang Yang finished his Ph.D. education at College Park, University of Maryland in 1995. Recently he won the Talent Award of Innovation and Entrepreneur of Jiangsu Province in 2012. His research focus include phenotypic assay development and application； examination and characterization of therapeutic antibodies and their targets.； Dr. Guang Yang familiar with various disease areas, such as cancer, inflammatory, auto-immune, infectious, metabolic disorders, etc. He has a solid academic background, and has 20 years’ work experience in R&D department of global pharmaceutical companies and drug discovery institutes. The R&D team led by him obtained extraordinary achievements in the field of research and drugs discovery. He had established a wide range of cooperation with domestic and foreign partners.

　　**Thanks for Promega's Support on Lunch Session:

　　12:15-12:45 Lunch (Please book in advance for free lunch boxes)

　　12:45-13:15 ADCC Reporter Bioassay: A Novel, Bioluminescent Cell-Based Assay for Quantifying Fc Effector Function of Antibodies (Presented by Chang Liu, Ph.D, Promega(Beijing) Biotech Co.,Ltd)

Shuttle Bus:

合作媒体：